|
Post by radgray68 on Jul 12, 2019 18:42:01 GMT -5
"It is not the critic who counts; not the man who points out how the strong man stumbles, or where the doer of deeds could have done them better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood; who strives valiantly; who errs, who comes short again and again, because there is no effort without error and shortcoming; but who does actually strive to do the deeds; who knows great enthusiasms, the great devotions; who spends himself in a worthy cause; who at the best knows in the end the triumph of high achievement, and who at the worst, if he fails, at least fails while daring greatly, so that his place shall never be with those cold and timid souls who neither know victory nor defeat." -Theodore Roosevelt-
Keep chugging away Mike. Al Mann, Hakan Edstrom and Matt Pfeifer, couldn't stop the short's attacking our company either.........but many of us know you'll do it.
|
|
|
Post by lifebreath on Jul 12, 2019 19:24:46 GMT -5
"It is not the critic who counts; not the man who points out how the strong man stumbles, or where the doer of deeds could have done them better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood; who strives valiantly; who errs, who comes short again and again, because there is no effort without error and shortcoming; but who does actually strive to do the deeds; who knows great enthusiasms, the great devotions; who spends himself in a worthy cause; who at the best knows in the end the triumph of high achievement, and who at the worst, if he fails, at least fails while daring greatly, so that his place shall never be with those cold and timid souls who neither know victory nor defeat." -Theodore Roosevelt- Keep chugging away Mike. Al Mann, Hakan Edstrom and Matt Pfeifer, couldn't stop the short's attacking our company either.........but many of us know you'll do it. Unfortunately those you have named with the exception of Al Mann never entered the arena. Those that entered the arena are the ones who risked their own hard earned money for a cause they believed in and Al Mann who put up 1billion dollars of his own money to help make the lives of people who suffer from diabetes better. Those you mention take no risks whatsoever, and never did. They receive unconscionable paychecks, bonuses and stock options without risk or accountability for their incompetence. All that ever mattered to them was their fat paycheck. When they leave the company with a smile on their face and the money of shareholders who worked hard to earn it they just float away on golden parachutes.
|
|
|
Post by mytakeonit on Jul 12, 2019 20:12:04 GMT -5
Here's a tribute to all the unnamed soldiers who constantly buy MNKD shares trying to keep it out of the short minded souls hands who vigilantly attack our beloved company. I won't name names ... but hopefully, Mike C will make a fighting chance for this sports of ours. Give us a sportsing chance to make a lot of $$$.
But, that's mytakeonit
|
|
|
Post by cretin11 on Jul 13, 2019 1:05:21 GMT -5
plytle , I saw your post just after I posted above - the point is spot on.
mnkdfann , the point was not whether there were options available, but rather rtmd implied it would be a malpractice risk to prescribe an inhaled medication for "an ailment whose hallmarks are airway constriction and difficulty breathing." Care guidelines for asthma illustrate the silliness of that claim. Litigation is chock-full of silly claims. If I would ever consider prescribing inhaled epinephrine, I would only do so with an accompanying epipen script. It's up to the patient at that point which or both they want to fill, but at least I'll be able to document to cover myself that I offered an injected version to my patients. You have to remember that judges do not have medical knowledge and lawyers are able to exploit any loophole and make it look like a highway tunnel. All I will add to this is be careful about how much of a "no brainer" this is. I think it was mentioned before, the same was thought of Afrezza. I would also want to see that outcomes were as good or better than an injected epinephrine before considering a script. I'm not sure inducing anaphylaxis would be ethical, although I'm not an expert. I am way more weary of prescribing epinephrine than I would be for insulin because the margin for error is much wider with a chronic disease than one that can kill you within minutes. Just my opinion. Take it for what it's worth. Edit: To illustrate my point of how silly lawsuits can be, I'll share a story from a GI doctor I rotated with. He was treating a woman with diabetes who had gastroparesis. There aren't a lot of good options for it. About the only thing that is FDA approved is Reglan. So he prescribed her Reglan. A serious side effect of Reglan is tardive dyskinesia. It can be reversible if you stop Reglan soon after initial symptoms present themselves. He told her to stop taking the medication. He even documented that he told her to stop taking it. The problem was that he gave her a year's prescription of it right before she started showing signs of TD, and she kept taking it. The story doesn't make a lot of sense to me when you consider why she waited 10 years after he saw her to sue him, but that's supposedly what happened. Well, you're allowed to shred medical records after 6 years and that's what he did. So there went his proof that he told her to stop taking her medication and he ended up losing the case. So she developed a well-known side effect from the drug but the doctor lost a lawsuit because it's our responsibility to make sure the drug isn't harming our patients. There was proof that his treatment plan harmed her and no proof that he did his job to protect her. No patient's convenience is worth a lost lawsuit. stevil that’s an interesting tale but it doesn’t hold up. folks like to exaggerate so I get it (not saying you are, but rather whomever told you that was “stretching” things).
|
|
|
Post by sweedee79 on Jul 13, 2019 4:12:09 GMT -5
There is a statute of limitations on a medical malpractice suit, generally 2 to 6 years depending on the state... I've never heard of 10 years.
In order to win a case you need some pretty strong evidence.. most cases never go to court.. and defendant pays only for damages to the plaintiff.
No one likes a frivolous lawsuit.. most people can sniff those out pretty fast and put a stop to it.
|
|
|
Post by rtmd on Jul 13, 2019 6:47:05 GMT -5
There is a statute of limitations on a medical malpractice suit, generally 2 to 6 years depending on the state... I've never heard of 10 years. In order to win a case you need some pretty strong evidence.. most cases never go to court.. and defendant pays only for damages to the plaintiff. No one likes a frivolous lawsuit.. most people can sniff those out pretty fast and put a stop to it. Frivolous doesn't matter to malpractice lawyers, nor even to malpractice insurers. The lawyer takes a cut of whatever he can get and the insurer just turns around and raises the premium of the defendant. A woman went into a small town Indiana emergency room one night complaining of abdominal pain. The ER doctor did a standard work-up and couldn't find anything but as a malpractice precaution admitted her overnight. The next morning the family doctor on call did an even further work-up with standard tests and couldn't find anything, so he discharged her with a follow-up appointment with a gastroenterologist. That doctor did an even fuller work-up and couldn't find anything so he sent her to an Indiana University gastroenterology clinic in Indianapolis. After even a more detailed work-up they managed to discover a half centimeter diameter aneurysm in her pancreatic artery that was periodically rupturing. The woman turned around and sued everyone from the ER doctor up even though she had a standard of care work-up in each case. The insurers eventually settled. I don't know whether the patient received anything, but you can be guaranteed the doctors' malpractice premiums went up.
|
|
|
Post by sportsrancho on Jul 13, 2019 8:26:40 GMT -5
Nate talks about EpiPen. Manufacturing expansion, and how Afrezza it is very undervalued. And says the same thing about EpiPen some of the rest of us did:-)
|
|
|
Post by boca1girl on Jul 13, 2019 8:38:18 GMT -5
Nate starts at 27:26. MNKD comments at 38:06.
|
|
|
Post by lifebreath on Jul 17, 2019 15:08:11 GMT -5
The original news release was nothing but a red herring
|
|
|
Post by sayhey24 on Jul 17, 2019 15:39:25 GMT -5
Lifebreath - I am not sure you appreciated the PR. Its IMO huge news but an appreciation of the afrezza facility is needed. Here is a key phrase - "This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships."
What partnerships? We know of UTHR but it says partnerships and we know RLS was moved to CA so I would say stay tuned. Mike said wait for July and we still have a few more weeks. While some like Mike K. don't I still have faith in Mike.
Additionally building this new facility separate from the afrezza production is a huge deal.
|
|
|
Post by mnholdem on Jul 17, 2019 15:54:11 GMT -5
The fill lines have always been separate from the equipment that produces the API powder. On the assumption that this is more than simply relocating the equipment from R&D to the production facility, at the minimum this PR suggested that is better able to respond to demand for other APIs in the pipeline.
I sure hope that it’s not any kind of “if we build it they will come” mentality at work here.
|
|
|
Post by hellodolly on Jul 17, 2019 15:54:36 GMT -5
Lifebreath - I am not sure you appreciated the PR. Its IMO huge news but an appreciation of the afrezza facility is needed. Here is a key phrase - "This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships." What partnerships? We know of UTHR but it says partnerships and we know RLS was moved to CA so I would say stay tuned. Mike said wait for July and we still have a few more weeks. While some like Mike K. don't I still have faith in Mike. Additionally building this new facility separate from the afrezza production is a huge deal. Sayhey, I posted the same sort of reply to Lifebreath on nearly the same issues but I've checked and don't see a reply except another post outlining a steam of failures he/she feels Mike C committed as CEO. "You're all in on Afrezza only? Do you see any other value with the rest of the business plan? I get Mike hasn't been able to deliver on the Afrezza script growth but it seems he's doing more than just putting all his eggs in one basket and would love to read your POV on that aspect of the MNKD strategy. Is it putting the cart before the horse, in your opinion? Do you think he should abandon all other efforts? With the execution of the TV ad campaign and expenditure of 9M dollars that doesn't seem to have had the desired affect, do we throw out the baby with the bath water." Read more: mnkd.proboards.com/thread/8970/michael-kovacocy-mannkind-comments#ixzz5tyDlV5PY
|
|
|
Post by lifebreath on Jul 17, 2019 16:07:24 GMT -5
Lifebreath - I am not sure you appreciated the PR. Its IMO huge news but an appreciation of the afrezza facility is needed. Here is a key phrase - "This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships." What partnerships? We know of UTHR but it says partnerships and we know RLS was moved to CA so I would say stay tuned. Mike said wait for July and we still have a few more weeks. While some like Mike K. don't I still have faith in Mike. Additionally building this new facility separate from the afrezza production is a huge deal. I clearly saw the implications eluded to in the release. I remain both a sceptic and a cynic. I hope to be proven wrong. Until there is an agreement announced that provides for significant upfront money I will remain sceptical
|
|
|
Post by sayhey24 on Jul 17, 2019 17:59:29 GMT -5
Lifebreath - I am not sure you appreciated the PR. Its IMO huge news but an appreciation of the afrezza facility is needed. Here is a key phrase - "This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships." What partnerships? We know of UTHR but it says partnerships and we know RLS was moved to CA so I would say stay tuned. Mike said wait for July and we still have a few more weeks. While some like Mike K. don't I still have faith in Mike. Additionally building this new facility separate from the afrezza production is a huge deal. Sayhey, I posted the same sort of reply to Lifebreath on nearly the same issues but I've checked and don't see a reply except another post outlining a steam of failures he/she feels Mike C committed as CEO. "You're all in on Afrezza only? Do you see any other value with the rest of the business plan? I get Mike hasn't been able to deliver on the Afrezza script growth but it seems he's doing more than just putting all his eggs in one basket and would love to read your POV on that aspect of the MNKD strategy. Is it putting the cart before the horse, in your opinion? Do you think he should abandon all other efforts? With the execution of the TV ad campaign and expenditure of 9M dollars that doesn't seem to have had the desired affect, do we throw out the baby with the bath water." Read more: mnkd.proboards.com/thread/8970/michael-kovacocy-mannkind-comments#ixzz5tyDlV5PYWhat I see popping the share price is RLS. What they are working on should far exceed what GWPH has. There is also significant funding behind the RLS operation. IMO its the real deal. I see UTHR paying the bills near term. It will be interesting what is recognized in Q2 for UTHR services. Hopefully a good amount of Danbury salaries for making the new facility. Afrezza long term will deliver. Ollie Branicourt said it won't be a viable product until 2020. I thought 2019. I was wrong but I hope Ollie is correct. Afrezza should be the greatest selling drug of all time. No need for any T2 meds once they start using it. Martin Cooper invented the cell phone in 1973, things take time. Aged pointed to NKTR the other day. I am hoping to see a pop like that and as they say hope springs external.
|
|
|
Post by lifebreath on Jul 18, 2019 9:38:34 GMT -5
Lifebreath - I am not sure you appreciated the PR. Its IMO huge news but an appreciation of the afrezza facility is needed. Here is a key phrase - "This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships." What partnerships? We know of UTHR but it says partnerships and we know RLS was moved to CA so I would say stay tuned. Mike said wait for July and we still have a few more weeks. While some like Mike K. don't I still have faith in Mike. Additionally building this new facility separate from the afrezza production is a huge deal. Sayhey24 do you want to reconsider this post. There are now less than two weeks remaining in July. If there was a deal that could raise SP to be announced this month why would MC dilute at $1.04 now. The two recent announcements were a weak attempt to keep share price up before dilution.
|
|